LENZ Therapeutics (LENZ) Company Report

LENZ Therapeutics launched its presbyopia product, Viz, in early October 2025, following its approval in late July 2025, with early feedback indicating rapid and long-lasting efficacy.
Initial launch metrics for Viz show strong uptake, with 5,000 scripts filled and 2,500 doctors prescribing within the first four weeks, and over 90% awareness among target doctors.
The company plans to initiate a direct-to-consumer (DTC) campaign in Q1 2026, featuring Sarah Jessica Parker as spokesperson, leveraging digital targeting for specific demographics.
Viz is positioned as a "category of one" due to its superior efficacy, working three times longer and for a six times larger population compared to competitors like Vuity.
LENZ is expanding internationally with NDA submissions in South Korea and Greater China, and a partnership for Canada, alongside direct registration efforts in Europe.

3 days ago

Transcript

LENZ Therapeutics Provides Update on Viz Product Launch and Commercial Strategy

LENZ

Product Launch

LENZ Therapeutics launched its presbyopia product, Viz, in early October 2025, following FDA approval in late July 2025.
Within the first four weeks of launch, Viz achieved 90%+ doctor awareness, 2,500 prescribing doctors (with 40% writing more than once), and 5,000 filled scripts.
The company plans to initiate its Direct-to-Consumer (DTC) campaign in Q1 2026, featuring Sarah Jessica Parker as the spokesperson, utilizing digital advertising to target specific demographics.
Viz is positioned as a "category of one" due to its pupil-selective miotic, aceclidine, offering superior efficacy and duration compared to competitors, and is expected to work for a six times larger patient population.
International expansion efforts include NDA submissions in South Korea and Greater China, an agreement for Canada, and direct pursuit of registration in Europe, tapping into a global market of 1.8 billion presbyopes.

3 days ago

Transcript

LENZ Therapeutics Provides Update on Presbyopia Eye Drop Launch and Financial Outlook

LENZ

Product Launch

Guidance Update

New Projects/Investments

LENZ Therapeutics' presbyopia eye drop was approved in late July and launched in early October 2025, with initial launch metrics after four weeks including 90% doctor awareness, samples at 7,000 doctor offices, 2,500 doctors writing scripts, and over 5,000 paid and filled scripts.
The company plans to initiate a direct-to-consumer (DTC) campaign in Q1 2026, focusing on new patient starts (NRx) in the first half of the year and transitioning to refill rates in the second half.
LENZ maintains a strong cash balance of $325 million (at product launch) and expects to achieve cash flow positivity by 2027 without requiring additional capital raises.
International expansion efforts include licensing agreements for China (submission in June 2025), Southeast Asia, and Canada, with a recent submission for South Korea and the company driving the European submission itself.

4 days ago

Transcript

LENZ Therapeutics Provides Update on Viz Launch and Commercial Strategy

LENZ

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

LENZ Therapeutics launched its presbyopia eye drop, Viz, in early October 2025, following FDA approval in late July.
Initial launch metrics as of early November 2025 (after four weeks) include over 90% awareness among doctors, samples at 7,000 doctor offices, and 2,500 doctors writing prescriptions, totaling over 5,000 paid and filled scripts.
The company plans to initiate a Direct-to-Consumer (DTC) campaign in Q1 2026 to drive patient demand, with a focus on tracking new patient starts in the first half of the year and refill rates in the second half.
LENZ has a healthy cash balance of approximately $325 million as of the product launch and expects to reach cash flow positivity in 2027, with no plans to raise additional capital.
The company is actively pursuing international expansion, with submissions in China and South Korea, and licensing agreements in Canada, while driving the European submission itself.

4 days ago

Transcript

LENZ Therapeutics Provides Update on Viz Launch and Commercial Strategy

LENZ

Product Launch

New Projects/Investments

LENZ Therapeutics launched its presbyopia eye drop, Viz, in early October 2025, following FDA approval in late July 2025.
Initial market performance for Viz has been positive, with 90% brand awareness by early November, over 7,000 offices receiving samples, and more than 2,500 doctors writing scripts, leading to over 5,000 filled prescriptions in the first four weeks.
Viz is noted for its high efficacy, restoring near vision within 10-15 minutes and lasting a full workday, with a favorable safety profile showing less headache incidence than observed in clinical trials.
A direct-to-consumer (DTC) advertising campaign, featuring Sarah Jessica Parker, is set to begin in Q1 2026, targeting specific demographics such as contact lens wearers and post-LASIK patients.
The product is priced at $79 for a one-month supply, with a three-month supply available for under $98 (or $66 per pack) through e-pharmacy, and is showing higher uptake in urban areas and among the 45-55 age group.

5 days ago

Transcript

LENZ Therapeutics Reports Initial Viz Launch Performance and Q1 DTC Strategy

LENZ

Product Launch

Revenue Acceleration/Inflection

Guidance Update

LENZ Therapeutics launched its presbyopia eye drop, Viz, in early October following FDA approval in late July.
Initial market reception has been strong, with 90% brand awareness by early November, over 2,500 doctors writing scripts, and more than 5,000 filled prescriptions in the first four weeks.
Viz is noted for its high efficacy, restoring near vision within 10-15 minutes for a full workday, and a favorable safety profile with a significantly lower incidence of headaches reported in the market compared to clinical trials.
A direct-to-consumer (DTC) campaign, featuring Sarah Jessica Parker, will commence in Q1, targeting key demographics such as contact lens wearers and post-LASIK patients.
The product is priced at $79 for a one-month supply (or $66 per pack for a three-month supply via e-pharmacy), with initial e-pharmacy data indicating higher adoption among the 45-55 age group and in urban areas.

5 days ago

Transcript

LENZ Therapeutics Provides Update on VIZZ Launch and Future Strategy

LENZ

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

LENZ Therapeutics launched its presbyopia eye drop, VIZZ, in early October 2025, following FDA approval in late July 2025.
Initial launch performance (first 8-9 weeks) has been strong, with 90% brand awareness, over 7,000 offices receiving samples, over 2,500 doctors writing scripts, and more than 5,000 filled prescriptions in the first four weeks.
The product is effective, restoring near vision within 10-15 minutes for the full workday (anecdotally 10-12 hours), and exhibits a favorable safety profile with fewer headaches observed in the market compared to clinical trials.
A direct-to-consumer (DTC) advertising campaign, featuring Sarah Jessica Parker as spokesperson, is scheduled to begin in Q1 2026, targeting specific demographics such as contact lens wearers, post-LASIK patients, and the active aging group.
VIZZ is priced at $79 for a one-month supply, with a three-month supply available for under $98 (equating to $66 per pack) through e-pharmacy, and the company's market assumptions are based on 5 refills a year for a potential $3 billion market.

5 days ago

Transcript

LENZ Reports Q3 2025 Results and VIZ Launch Progress

LENZ

Product Launch

Earnings

Guidance Update

LENZ successfully launched its VIZ product in the U.S. in early October 2025, following FDA approval in July. As of the end of October, over 2,500 doctors have prescribed VIZ, with 40% writing multiple prescriptions, resulting in over 5,000 paid scripts filled.
The company strengthened its balance sheet in October 2025 by completing a direct placement that raised over $123 million, bringing its total cash position to approximately $324 million.
For Q3 2025, LENZ reported $12.5 million in total license revenue from strategic partnerships, including milestones from Corksol Pharmaceuticals and an upfront payment from Laboratoires Théa.
Total operating expenses for Q3 2025 increased to $31.4 million, a 44% increase over Q2, primarily driven by SG&A expenses of $27.6 million for commercial launch activities. Research and development expenses decreased by 58% sequentially to $3.8 million.
LENZ announced Sarah Jessica Parker as the spokesperson for its direct-to-consumer campaign, which is set to launch in early 2026, with an anticipated 2026 commercial spend of $80 million-$100 million.

Nov 5, 2025, 1:30 PM

Transcript

LENZ Therapeutics Reports Q3 2025 Financial Results and VIZZ Commercial Launch Progress

LENZ

Earnings

Product Launch

New Projects/Investments

LENZ Therapeutics reported a net loss of $16.7 million or $0.59 per share for the third quarter ended September 30, 2025, with $12.5 million in license revenue.
The company's pro forma cash, cash equivalents, and marketable securities were approximately $324.0 million as of September 30, 2025.
VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval on July 31, 2025, and its commercial launch began in October 2025, resulting in over 5,000 prescriptions filled through October 2025 by over 2,500 unique prescribers.
LENZ partnered with Sarah Jessica Parker as the direct-to-consumer campaign spokesperson, with the campaign anticipated to launch in Q1 2026.
The company achieved $10 million in milestones from CORXEL Pharmaceuticals and signed an exclusive licensing agreement with Laboratoires Théa for Canada, which could yield over $70 million in milestone payments plus tiered, double-digit royalties.

Nov 5, 2025, 1:23 PM

8-K

LENZ Therapeutics Announces Commercial Availability of VIZZ in the U.S.

LENZ

Product Launch

New Projects/Investments

LENZ Therapeutics, Inc. announced the commercial product availability of VIZZ™ (aceclidine ophthalmic solution) 1.44% in the United States on September 30, 2025.
VIZZ is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, a condition impacting approximately 128 million adults in the United States.
Professional product sample distribution has been initiated nationwide, with commercial product shipments to consumers starting in October and broad availability by mid-Q4 2025.